





CLDN18 Monoclonal Antibody

Product Code	CSB-RA005498A2HU
Storage	Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Uniprot No.	P56856
Immunogen	Recombinant Human CLDN18 protein
Species Reactivity	Human
Tested Applications	ELISA, FC; Recommended dilution: FC:1:50-1:200
Form	Liquid
Conjugate	Non-conjugated
Storage Buffer	Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Purification Method	Affinity-chromatography
Isotype	hIgG1
Clonality	Monoclonal
Product Type	Recombinant Antibody
Immunogen Species	Homo sapiens (Human)
Research Area	Signal transduction
Gene Names	CLDN18
Accession NO.	25E3

Image



Untransfected KATO3 cells (green line), transfected Human CLDN18.2 KATO3 stable cells (red line) and transfected Human CLDN18.1 NIH-3T3 stable cells (blue line) were stained with anti-CLDN18 antibody ($2\mu\text{g}/1 \times 10^6$ cells), washed and then followed by FITC-conjugated Goat Anti-Human IgG, Fc γ antibody (CSB-PA271513) and analyzed with flow cytometry.



The Binding Activity of Human CLDN18.2 with Anti-CLDN18 recombinant antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CLDN18.2 (CSB-MP005498HU(A5)) at $5\mu\text{g}/\text{mL}$ can bind Anti-CLDN18 recombinant antibody, the EC_{50} is $2.947\text{-}8.782\text{ ng}/\text{mL}$.



Description

The humanized IgG1 recombinant CLDN18 monoclonal antibody specifically targets the tumor-associated antigen (TAA) CLDN18 and possesses potential immunostimulating and antineoplastic activities. It is purified through the affinity-chromatography method. This CLDN18 antibody shows reactivity with human CLDN18.2 protein and has been validated in ELISA and FC applications. It may be used to kill CLDN18.2-expressing tumor cells and inhibit cell proliferation.

Intrinsic characteristics of CLDN18.2 including involvement in tumor development and progression and availability for monoclonal antibody binding due to its exposed extracellular loops, make CLDN18.2 become an attractive molecule for targeted therapy and push the further development of CLDN18 antibodies. Chin J Cancer Res showed that zolbetuximab, a chimeric IgG1 CLDN18.2 monoclonal antibody, can specifically bind to CLDN18.2 on the tumor cell surface, hence eliciting ADCC, CDC, apoptosis and suppressing cell proliferation. Preclinical studies have successfully validated that zolbetuximab can eliminate cancer cells and control diseases. Prabhsimranjot Singh et al. found that claudiximab, a CLDN18.2 monoclonal antibody, played immune-stimulating and antitumor roles in animal models with gastric cancer.